2.Determination of plasma EBV DNA in 91 children with EBV-associated diseases.
Hong-Mei DUAN ; Yao YAO ; Zheng-De XIE ; Jing YAN ; Ying-Hui HU ; Yuan YAO ; Ling ZHOU ; Kun-Ling SHEN
Chinese Journal of Contemporary Pediatrics 2009;11(11):897-900
OBJECTIVETo determine the plasma level of Epstein Barr virus (EBV) DNA in children with EBV associated diseases, and to investigate the dynamic changes of EBV DNA level after initial infection as well as the relationship between EBV DNA level and the diseases severity.
METHODSThe subjects consisted of 73 children with primary EBV infection (infectious mononucleosis, pneumonia,etc.) and 18 children with severe EBV-associated diseases (chronic active EBV infection, hemophagocytic lymphohistiocytosis, etc.). The plasma EBV DNA level was detected by a real-time PCR assay.
RESULTSThe plasma EBV DNA level decreased with the infection time in children with primary EBV infection. Two weeks after infection, plasma EBV DNA was almost undetectable. The positive rate of plasma EBV DNA in children with severe EBV associated diseases increased significantly when compared with that in children with primary EBV infection (89% vs 16%; p<0.05).
CONCLUSIONSThe level of EBV replication may be reduced with the infection time. Dynamic determination of blood EBV DNA is useful for the evaluation of disease severity in children with EBV infection.
DNA, Viral ; blood ; Epstein-Barr Virus Infections ; virology ; Humans ; Infectious Mononucleosis ; virology ; Lymphohistiocytosis, Hemophagocytic ; virology ; Virus Replication
4.Investigation of lymphoma patients' EBV infection status.
Xiao-Yi WANG ; Xi-Nan CEN ; Han-Yun REN
Journal of Experimental Hematology 2014;22(6):1584-1590
This study was purposed to investigate the EBV infection status of lymphoma patients from January 2008 to April 2012 in the First Hospital of Peking University. All the candidates have been detected for EBV which was either peripheral blood EBV DNA or ISH EBER in pathology from January 2008 to April 2012. The information on their sex, age, pathological type, peripheral blood EBV DNA and ISH EBER was collected, the positive rate of different EBV tests was studied, and the different characteristics of the EBV(+) and EBV(-) group were also explored. And Kaplan-Meier and Cox survival analysis was applied to investigate the EBV's effect on overall survival of these patients. The results showed that among 169 lymphoma patients, the positive rates of EBV EBER in extranodal NK/T cell lymphoma, angioimmunoblastic T cell lymphoma and peripheral T-cell lymphoma were 84.8%, 72.7% and 40.0%, respectively, and were ranged as the top three. The positive rate of EBV in DLBCL was relatively lower (16.7%) than that in above three types of lymphoma. The positive rate of peripheral blood EBV DNA of the elderly EBV(+) DLBCL was 50%. One out of 10 HL patients was subjected to EBER detection, the result of which was positive. The positive rate of peripheral blood EBV DNA of HL was 10%. Both the T cell lymphoma proportion and the rate of B symptom were higher in EBV(+) group than in EBV(-) group. In all the EBER(+) cases, the difference of OS between EBV(+) and EBV(-) patients was statistically significant. In multiple-factor survival analysis, peripheral blood EBV DNA positive was an independent risk factor for poor prognosis in the patients with lymphoma. It is concluded that EBV is closely related to extranodal NK/T cell lymphoma, angioimmunoblastic T cell lymphoma and peripheral T-cell lymphoma. Peripheral blood EBV DNA positive is an independent risk factor for poor prognosis in lymphoma patients.
Epstein-Barr Virus Infections
;
complications
;
Herpesvirus 4, Human
;
Humans
;
Immunoblastic Lymphadenopathy
;
Lymphoma
;
virology
;
Survival Analysis
5.Epstein-Barr virus and the origin of Hodgkin lymphoma.
Martina VOCKERODT ; Fathima Zumla CADER ; Claire SHANNON-LOWE ; Paul MURRAY
Chinese Journal of Cancer 2014;33(12):591-597
Although Epstein-Barr virus (EBV) is present in the malignant Hodgkin/Reed-Sternberg (HRS) cells of a proportion of cases of classical Hodgkin lymphoma (cHL), how the virus contributes to the pathogenesis of this disease remains poorly defined. It is clear from the studies of other EBV-associated cancers that the virus is usually not sufficient for tumor development and that other oncogenic co-factors are required. This article reviews what is known about the contribution of EBV to the pathogenesis of cHL and focuses on emerging evidence implicating chronic inflammation as a potential oncogenic co-factor in this malignancy.
Epstein-Barr Virus Infections
;
Herpesvirus 4, Human
;
Hodgkin Disease
;
virology
;
Humans
;
Reed-Sternberg Cells
7.Research progress on epstein-barr virus and its related lymphoma.
Teng-Teng WANG ; Tian YUAN ; Yi-Zhuo ZHANG
Journal of Experimental Hematology 2014;22(6):1775-1779
Epstein-Barr virus (EBV) belongs to r-DNA herpes virus family and the first discovered virus associated with human tumors. Numerous studies have found that EBV infection is related to the occurrence of a variety of lymphomas, such as Hodgkin's lymphoma, Burkitt's lymphoma, NK/T-cell lymphoma, HIV-related lymphoma and diffuse large B-cell lymphoma. Recent studies indicated that the gene expression products of EBV latent infections play an important role in the lymphoma, and these findings provide the theoretical basis for the treatment of EBV-related lymphoma. This review mainly discusses the progress in the mechanism and the therapy of EBV-related lymphoma.
Epstein-Barr Virus Infections
;
complications
;
Herpesvirus 4, Human
;
Humans
;
Lymphoma
;
virology
10.Research advance on Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Journal of Experimental Hematology 2011;19(6):1541-1544
Epstein-Barr virus (EBV) is the major triggering factor producing virus-associated hemophagocytic syndrome (VAHS). The clinical manifestations were various and it's diagnosis should meet HLH-2004 criteria as well as EBV-positive, and familial hemophagocytic lymphohistiocytosis and lymphoma-associated hemophagocytic syndrome must be ruled out, too. In terms of treatment, combination of dexamethasone, VP-16 and cyclosporin A is the first choice, if they do not work, hematopoietic stem cell transplantation can be done. In this review, the recent advance on pathogenesis, clinical features, diagnostic problems, treatment strategies and prognosis of EBV-HLH have been described.
Epstein-Barr Virus Infections
;
Herpesvirus 4, Human
;
Humans
;
Lymphohistiocytosis, Hemophagocytic
;
virology